The maturation of new life sciences technology will lead to a new generation of cures hitting the market in coming years, which means the business of building and operating a new generation of biomanufacturing plants offers a significant real estate opportunity.  “Every few decades, there are dramatic shifts to the industry,” said Matt Gardner, leader of CBRE's advisory life sciences practice. “The last one was when the whole industry shifted towards monoclonal antibodies, these complex folded proteins. We’ve entered the cell-gene therapy era.” While deal volume has cooled during the recent period of market and financial uncertainty, demand is only forecast to grow as a wave of life sciences developments mature. Cell and gene therapy, which results in more personalized medicine and smaller-scale manufacturing runs, may have nearly a dozen FDA approvals this year. That means new facilities will be needed as more products come online. The potential for smaller-scale facilities opens up new opportunities to develop and build on smaller, more urban lots. These kinds of developments have already taken shape in markets such as Boston, Philadelphia, Maryland, the Bay Area and in North Carolina. CRB, a firm that analyzes the life sciences and pharma industry, predicts 6% to 10% growth in manufacturing in each of the next three years, and almost all of the 500 companies it surveys annually have plans to expand, with a significant portion making capital investment in manufacturing set… Read Full Story  | 
